Von Eschenbach to resign from National Cancer Institute post

FDA acting commissioner Andrew von Eschenbach said this week he would resign from his other job, as director of the National Cancer Institute (NCI), effective June 10. Von Eschenbach’s holding of both positions had raised questions of a potential conflict of interest. He has led NCI since 2002. Von Eschenbach became acting commissioner in September 2005 and in March was nominated by President Bush to lead the regulatory agency. His confirmation remains “in limbo” amid debate on the FDA’s position on the OTC status of Barr’s emergency contraceptive pill Plan B.
You must be a registered member of MMM to post a comment.

Content marketing is not advertising in the old sense. In its use of social media, content marketing challenges consumers while relying on their input. It is proactive and responsive to their concerns, needs and energy. Content marketing has become the new voice of marketing. Learn what you need to know and how pharma marketers can adapt to this innovative venture into social media by clicking here for access.

Email Newsletters